Sunshine Biopharma, Inc.
SBFM
$1.48
$0.085.71%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -41.81% | -71.39% | -23.06% | -13.94% | 84.21% |
| Total Depreciation and Amortization | 49.08% | 54.42% | 56.40% | 49.80% | 59.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12,936.29% | 8,748.33% | -100.00% | -- | -99.93% |
| Change in Net Operating Assets | 60.94% | 62.60% | -1.28% | -72.66% | -47,729.45% |
| Cash from Operations | 39.69% | 28.95% | -9.35% | -42.76% | -41.73% |
| Capital Expenditure | 76.27% | -18.43% | -1,003.79% | -1,915.82% | -77.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.25% | -35.93% | 69.18% | -31.73% | -978,800.00% |
| Cash from Investing | 38.74% | -27.97% | -62.94% | -267.78% | 85.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 366.87% | 158.55% | 180.76% | 169.71% | 73.70% |
| Issuance of Common Stock | -46.09% | -12.04% | -69.44% | 195.19% | 155.85% |
| Repurchase of Common Stock | 100.00% | 100.00% | 100.00% | -480.24% | -480.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -16.66% | 50.82% | -53.88% | 173.74% | 436.31% |
| Foreign Exchange rate Adjustments | -2,049.64% | 141.07% | -1,077.63% | -321.27% | -89.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.32% | 85.38% | -400.52% | -19.37% | 69.42% |